What are the predictors of Fabry’s disease progression despite enzyme therapy?

Dr. Niccolo Maurizi, a Fabry's disease researcher from Lausanne, Switzerland, discusses key insights on this rare condition. He highlights the complexities of Fabry's disease and its systemic effects, particularly on heart health. The conversation dives into enzyme therapy, differentiating classical and late-onset forms, and the vital role of early intervention in halting progression. Maurizi emphasizes findings from a Swiss registry study, showcasing how timely therapy can prevent severe cardiac issues like left ventricular hypertrophy.